What tirzepatide costs at the 15 mg dose (the maximum studied dose) — compounded flat pricing vs brand-name self-pay tiers.
15 mg is the maximum dose studied in SURMOUNT-1, where it produced 22.5% mean weight loss over 72 weeks. It's where flat-rate compounded pricing offers the best cost-per-mg value. Compounded flat-rate pricing is identical at this dose; brand-name self-pay differs.
| Option | Type | From / month | FDA status |
|---|---|---|---|
| NexLife Editor's pick | Compounded, flat | $186/mo* | Not FDA-approved |
| Zepbound® LillyDirect (15 mg, within 45-day window) | Brand vial | $449/mo | FDA-approved |
| Zepbound® standard self-pay (15 mg, window missed) | Brand vial | $1049/mo | FDA-approved |
| Brand retail (any dose) | Brand pen | ~$1,086/mo | FDA-approved |
Verified July 2026. At 15 mg, compounded flat pricing stays at $186 while brand self-pay is $449–$1049. See the full price-by-dose guide.
15 mg is the maximum dose studied in SURMOUNT-1, where it produced 22.5% mean weight loss over 72 weeks. It's where flat-rate compounded pricing offers the best cost-per-mg value. Your clinician sets the titration schedule based on tolerance and response; side effects (mostly mild GI symptoms) are usually most noticeable when stepping up to a new dose. Compounded tirzepatide is not FDA-approved, and eligibility is determined by a licensed clinician. See safety & eligibility.
Compounded flat-rate pricing is $186/month at 15 mg; brand-name Zepbound self-pay is about $449/month within LillyDirect's 45-day window (up to $1049 otherwise). Compounded is not FDA-approved. See NexLife pricing
Maintenance doses are typically higher (often 10–15 mg) and chosen by your clinician after titration. Your schedule is individualized.
No. Compounded tirzepatide is not FDA-approved. Only brand-name Mounjaro (type 2 diabetes) and Zepbound (chronic weight management), made by Eli Lilly, are FDA-approved. Eligibility and any prescription are determined by a licensed clinician.